Kanna is Sceletium tortuosum, a low succulent from the arid Karoo and Namaqualand regions of South Africa, traditionally fermented and chewed by Khoisan communities under the name kougoed. It is not federally scheduled in the United States, FDA has taken no enforcement action against it of any kind, and the published clinical safety record — small as it is — is unusually clean. The uncertainty around kanna is not about risk. It is about legal basis: whether it qualifies as a lawful dietary ingredient rests on documentation that nobody has been able to produce.
That distinction matters, and almost nothing written about kanna makes it. This post separates the two questions and explains what a supplier has to show us before we would stock it. Botanical Blends is a distributor and retailer — we carry other companies' brands and formulate nothing — so our only real control is what we agree to shelve. This reflects the position as of 30 July 2026.
Quick answer
| Question | Where it stands |
|---|---|
| Is kanna a controlled substance? | No. It is not on any federal schedule. |
| Has FDA acted against it? | No. It is absent from the Dietary Supplement Ingredient Directory, from import alerts, and from the DoD prohibited ingredients list. |
| Is the safety record good? | By the standards of this category, yes — but the published trials are small and none runs past about three months. |
| So what is the problem? | Legal basis. There is no confirmed pre-1994 marketing history, and only one new dietary ingredient notification, whose outcome is not public. |
| Any state issues? | Louisiana's controlled-substances statute captures the genus by name, with an exemption for properly labelled dietary supplements meeting specific conditions. |
| Vapes or nasal sprays? | No. Non-ingestible forms fall outside the dietary supplement definition entirely. |
The plant
Kanna belongs to the ice-plant family, Aizoaceae. Current taxonomic references treat Sceletium tortuosum as a synonym of Mesembryanthemum tortuosum, which sounds like botanical housekeeping until you get to the Louisiana section below, where the naming turns out to matter a great deal.
The traditional preparation involves crushing and fermenting the aerial material, which is then chewed. The constituents of interest are a group of alkaloids: mesembrine, mesembrenone, mesembrenol and mesembranol, along with several minor relatives. Their proportions vary considerably between wild populations, which is one reason standardised extracts exist at all.
Published pharmacology describes kanna alkaloids as interacting with serotonin transport, with additional phosphodiesterase-4 activity, and describes monoamine oxidase A activity for mesembrine in particular. We mention that mechanism for one reason only — it is why the interaction warning further down this page is a real consideration rather than boilerplate. It is not a statement about what any product does, and nothing here should be read as one.
Is kanna legal in the United States?
Federally, there is no prohibition. Kanna does not appear on any DEA schedule. There is no pending scheduling action. It is not named in the July 2026 Federal Register notices — FR Doc 2026-13580, covering 7-hydroxymitragynine above a specified concentration, and FR Doc 2026-13581, covering mitragynine pseudoindoxyl, MGM-15 and MGM-16 with no threshold — all kratom-derived or kratom-related alkaloids from an entirely different plant family. Kanna has no relationship to any of that. The timeline for that action is in our explainer on the DEA scheduling notices.
FDA has taken no action. We searched for it and found nothing: no import alert, no warning letters naming Sceletium, no entry in the Dietary Supplement Ingredient Directory in any category, and no listing on the Department of Defense prohibited dietary supplement ingredients list. A real mainstream supplement channel exists — dozens of verified labels in FDA's own Dietary Supplement Label Database, from established retail brands.
Louisiana is the state exception, and it is a nomenclature problem. Louisiana's controlled-substances statute lists the genus Mesembryanthemum. Because current taxonomy treats Sceletium tortuosum as a synonym of Mesembryanthemum tortuosum, kanna is most likely captured, and the penalties under that statute are serious. The same statute, however, exempts any dosage form labelled as a dietary supplement that is manufactured under federal good manufacturing practice rules for supplements, by a facility registered with FDA, with serious adverse event reporting in place. Two honest caveats: no Louisiana court has interpreted the genus listing, so the capture is a botanical inference rather than a holding; and the exemption is conditional, which means it only helps a seller who actually holds that documentation.
The real issue: legal basis, not legal risk
Here is the part that gets skipped. Under US law, an ingredient may be sold in a dietary supplement if it was marketed in the United States before the October 1994 cutoff written into federal supplement law — an "old dietary ingredient" — or if a new dietary ingredient notification has been submitted to FDA. Kanna's position on both is unresolved.
On pre-1994 marketing, we could not find evidence. That does not prove none exists, but nobody has published it, and an absence of documentation is exactly what a regulator would find if they looked.
On notifications, there is exactly one across FDA's entire published list, filed in 2011 by the South African company behind a branded standardised extract sold under the name Zembrin. FDA has not posted its response letter, and the public record conflicts about what it said. Press material from the following year describes the ingredient as having completed the notification process. Trade reporting from 2025 describes it as having entered the US market on self-affirmed GRAS status after an unsuccessful notification. Those two accounts cannot both be right.
Our position is that the response letter is the buy gate. We will not stock kanna on the strength of a press release, and we would rather say so publicly than quietly carry an ingredient whose legal footing we cannot describe.
The circumstantial evidence cuts both ways. That the ingredient markets on self-affirmed GRAS rather than an FDA acknowledgement suggests the notification may not have landed cleanly. On the other hand, FDA has not placed Sceletium in the directory categories it uses for unnotified new dietary ingredients or for substances it does not consider dietary ingredients at all. Fifteen years of quiet is not an endorsement, but it is not nothing.
The safety record, and its limits
Kanna's clinical record is small but genuinely favourable. A handful of randomised controlled trials have been run on a standardised extract at modest daily doses, over periods of up to about three months, reporting adverse-event incidence no higher than placebo. Published animal toxicology on the same material did not identify adverse effects at the doses tested.
Two limits belong alongside that. First, no trial has run beyond roughly three months, so there is no long-term human data and we will not imply otherwise. Second, everything above was generated with one specific standardised article at a defined dose. It does not transfer automatically to a different extract at a different concentration, which brings us to the next section.
Serotonin, and the interaction warning that matters
Because kanna alkaloids act on serotonin transport and show monoamine oxidase A activity, combining kanna with medications that alter serotonin is a real pharmacological concern rather than a legal formality. Published safety guidance advises that kanna should not be used with drugs known to alter serotonin uptake or release, including SSRIs and SNRIs.
Any kanna product we carried would have to arrive from the brand with that warning already on the label, and we would repeat it on the product page: not for use with SSRIs, SNRIs, MAOIs or other serotonergic medications without medical advice. If you take any of those, this is a conversation for your prescriber.
Standardised extract versus "10:1 kanna"
This is where most of the practical risk in the kanna market actually sits.
The studied article is chemically specific. By the ingredient supplier's own published specification, it runs at approximately 0.4% total alkaloids, with mesembrenone and mesembrenol together making up at least 60% of the alkaloid fraction and mesembrine held to no more than 20%, at a defined daily dose. That is a defined material with defined study data behind it, and the specification is the supplier's claim, not ours.
An undefined "10:1 kanna extract" is not that material. It is a different chemical article with a different alkaloid ratio, and none of the safety data above applies to it by default. On FDA's article-specific logic, a concentrate would need its own notification even if kanna's baseline status were settled. We would decline both undefined concentration ratios and high-mesembrine products.
Adulteration is the other half of the problem. Independent testing in South Africa has repeatedly found products sold as kanna that contained no kanna at all or only trace amounts. Identity testing is therefore not optional here, and a certificate showing a disclosed alkaloid profile — not merely "total alkaloids" — is the minimum. It is also worth remembering what a certificate cannot do: a non-detect covers only the analytes the laboratory looked for, at one detection limit, and says nothing about anything the panel omitted. The field-by-field method is in how to read a certificate of analysis, and the reports for the brands we carry are published on the COA page.
Kanna vapes and nasal sprays are a hard no
This is not a grey area, and it is worth being blunt because the market is full of them.
Federal law defines a dietary supplement as a product intended for ingestion. FDA has said so directly in warning letters to sellers of inhaled products carrying supplement-style claims. An inhaled or nasally administered product falls outside the supplement framework entirely, losing the structure/function claim provisions the whole compliance model rests on. Every structure/function claim printed on a kanna vape becomes an unapproved drug claim. No notification and no GRAS determination can fix it, because both pathways run through ingestion. It also forfeits the Louisiana exemption above, which requires the dosage form to be labelled as a dietary supplement — you lose the defence and keep the exposure.
Where kanna sits in our catalogue
Nowhere, at present. We would want the response letter to that 2011 notification, a named standardised ingredient source, a disclosed alkaloid profile on a batch certificate, the manufacturing and registration documentation that supports the Louisiana exemption, and the serotonergic-interaction warning already on the label. That is a short list and it is not unreasonable, but no supplier has yet handed us all of it.
If you are comparing botanicals in this space, the parallel write-ups are what kava is and where it stands legally, the sourcing standard in noble versus tudei kava, and the safety record in what the kava liver record actually says.
Frequently Asked Questions
Is kanna legal in the United States?
It is not a controlled substance and FDA has taken no action against it. The open question is whether it qualifies as a lawful dietary ingredient, which turns on pre-1994 marketing evidence nobody has produced and one notification whose response letter FDA has not published. Louisiana has a genus-level statute with a conditional exemption for properly documented supplements.
Is kanna related to kratom?
No. Kanna is Sceletium tortuosum, a South African succulent in the ice-plant family. Kratom is a Southeast Asian tree in the coffee family. None of the compounds named in the 2026 federal scheduling action has any connection to kanna.
Can I take kanna with an antidepressant?
Not without asking your prescriber. Kanna alkaloids affect serotonin transport and show MAO-A activity, and published guidance advises against combining it with drugs that alter serotonin uptake or release, including SSRIs and SNRIs.
What is Zembrin?
A branded standardised Sceletium tortuosum extract with a defined alkaloid specification set by its supplier, and the article used in the published clinical trials. It is also the subject of the single new dietary ingredient notification on file for this plant.
Why avoid "10:1" kanna extracts?
Because an undefined concentration ratio is a chemically different article from the one that was studied, with a different alkaloid balance and no safety data of its own. We want a disclosed alkaloid profile, not a ratio. Store-wide terms are on the disclaimer page.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Legality depends on the specific formulation and applicable state law — check the rules where you live. Nothing here is legal advice.